US20080249065A1 - Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate - Google Patents

Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate Download PDF

Info

Publication number
US20080249065A1
US20080249065A1 US12/091,481 US9148106A US2008249065A1 US 20080249065 A1 US20080249065 A1 US 20080249065A1 US 9148106 A US9148106 A US 9148106A US 2008249065 A1 US2008249065 A1 US 2008249065A1
Authority
US
United States
Prior art keywords
ophthalmic pharmaceutical
pharmaceutical composition
patient
proline
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/091,481
Inventor
Franco Conti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Professional Dietetics SpA
Original Assignee
SOLARTIUM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37561156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080249065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SOLARTIUM LLC filed Critical SOLARTIUM LLC
Assigned to SOLARTIUM LLC reassignment SOLARTIUM LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONTI, FRANCO
Publication of US20080249065A1 publication Critical patent/US20080249065A1/en
Assigned to PROFESSIONAL DIETETICS S.R.L. reassignment PROFESSIONAL DIETETICS S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLARTIUM ENTERPRISED LIMITED
Assigned to PROFESSIONAL DIETETICS S.R.L. reassignment PROFESSIONAL DIETETICS S.R.L. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 026223, FRAME 0844 Assignors: SOLARTIUM ENTERPRISES LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention relates to ophthalmic pharmaceutical compositions, based on amino acids and sodium hyaluronate, with a protective and regenerating action on the corneal epithelial cells.
  • Dry eye syndrome is treated with eyedrops or gels (artificial tears) having a cleansing, lubricant and disinfecting action, which possess the chemico-physical characteristics of natural tears.
  • treatment usually involves administering topical preparations (eyedrops, ointments or artificial tears) with an antibiotic and anti-inflammatory activity.
  • the invention therefore relates to ophthalmic pharmaceutical compositions containing, as active ingredient, a combination of:
  • compositions according to the invention contain glycine, L-proline and sodium hyaluronate, and possibly L-lysine in the form of hydrochloride and L-leucine.
  • compositions according to the invention have a surprising effect as adjuvants: they aid regeneration of the epithelial microvilli and induce and accelerate corneal re-epithelialisation after eye surgery.
  • compositions according to the invention will therefore be used to treat:
  • compositions according to the invention will be applied to the eye 4-6 times a day, for a maximum of 3 months.
  • compositions according to the invention will contain the various active ingredients within the following percentage ranges by weight:
  • compositions according to the invention will contain the various active ingredients in the following percentages by weight:
  • Sodium hyaluronate is added separately to 100 kg of purified water, and stirred until the component has completely dissolved.
  • the two solutions are combined and made up to the final volume of 144 litres with purified water, checking that the pH value is between 6 and 7, and adjusting with citric acid or sodium bicarbonate if necessary.
  • the solution is filtered through an 0.22 ⁇ m filter under sterile conditions and placed in a container.
  • the protective and regenerative efficacy of the artificial tears according to the invention in reconstituting the corneal epithelium and stromal tissue in the case of pathological, traumatic, surgical, or parasurgical corneal lesions was investigated.
  • Group B the post-operative re-epithelialisation time was shortened from the usual 4-6 days to 2-3 days, and the administration of artificial tears, even after re-epithelialisation was complete, proved to prevent the appearance of haze and the dry eye syndrome typical of the first few months after surgery.

Abstract

This invention relates to ophthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.

Description

    FIELD OF INVENTION
  • The present invention relates to ophthalmic pharmaceutical compositions, based on amino acids and sodium hyaluronate, with a protective and regenerating action on the corneal epithelial cells.
    • PRIOR ART
  • No cure for hypolacrimation (dry eye) has yet been found. Dry eye syndrome is treated with eyedrops or gels (artificial tears) having a cleansing, lubricant and disinfecting action, which possess the chemico-physical characteristics of natural tears.
  • Artificial tears are fairly dense preparations, designed to remain in the eye at length and prevent rapid dilation.
  • These products considerably reduce the quality of vision after administration, and do not perform any wound-healing action.
  • Eye surgery designed to correct visual defects and remove cataracts is becoming increasingly common. These operations do not usually require stitches, but the wounds take some time to heal.
  • No wound-healing agents exist which promote rapid healing of corneal ulcerations, wounds and lesions of post-operative, pathological, traumatic or parasurgical origin.
  • Consequently, treatment usually involves administering topical preparations (eyedrops, ointments or artificial tears) with an antibiotic and anti-inflammatory activity.
  • There is therefore a need for new preparations which perform a regenerating action at epithelial level, and promote corneal re-epithelialisation and rapid healing.
    • DESCRIPTION OF THE INVENTION
  • It has now been found that the combination of some amino acids with sodium hyaluronate is particularly effective in promoting the process of reconstitution of the corneal epithelium and the stromal tissue in the case of pathological, traumatic, surgical or parasurgical corneal lesions.
  • The invention therefore relates to ophthalmic pharmaceutical compositions containing, as active ingredient, a combination of:
  • a) glycine and proline;
  • b) sodium hyaluronate; and possibly
  • c) lysine and leucine.
  • More particularly, the compositions according to the invention contain glycine, L-proline and sodium hyaluronate, and possibly L-lysine in the form of hydrochloride and L-leucine.
  • The compositions according to the invention have a surprising effect as adjuvants: they aid regeneration of the epithelial microvilli and induce and accelerate corneal re-epithelialisation after eye surgery.
  • The compositions according to the invention will therefore be used to treat:
      • slight, moderate or serious alterations of the tear film: the regeneration effect on the epithelial microvilli, which represent the fundamental substrate for effective restoration of the glycocalyx and consequently the tear film, drastically reduces the typical symptoms of dry eye.
      • patients who undergo laser treatments (PRK): the reduction in post-operative re-epithelialisation time prevents the appearance of haze and dry eye syndrome which are typical of the first few months after surgery;
      • relapsing and/or persistent corneal ulcers: the lasting re-epithelialisation effect prevents relapses and allows complete re-epithelialisation;
      • cataract removal surgery, phacoemulsification: the rapid healing effect on the corneal tunnel significantly reduces the discomfort felt by the patient.
  • The compositions according to the invention will be applied to the eye 4-6 times a day, for a maximum of 3 months.
  • The compositions according to the invention will contain the various active ingredients within the following percentage ranges by weight:
      • glycine 0.01 to 0.5%;
      • L-proline: 0.09 to 0.06%;
      • sodium hyaluronate: 0.5 to 0.1% and possibly
      • L-lysine hydrochloride: 0.01 to 0.02%;
      • L-leucine: 0.02 to 0.005%.
  • According to a preferred aspect, the compositions according to the invention will contain the various active ingredients in the following percentages by weight:
      • glycine: 0.1%
      • L-proline: 0.075%;
      • sodium hyaluronate: 0.3%;
  • and possibly
      • L-lysine hydrochloride: 0.014;
      • L-leucine: 0.011%.
  • The following is an example of a formulation according to the invention.
    • EXAMPLE
  • Eyedrop formulation
    Grams per
    INGREDIENTS unit dose
    Sodium hyaluronate 0.3000
    L-Proline 0.0752
    Glycine 0.1000
    L-Lysine HCl 0.0140
    L-Leucine 0.0108
    Sodium chloride 0.9000
    Distilled water to 100.0 mL
  • Preparation
  • 30 kg of purified water is mixed with L-proline, glycine, lysine HCl, L-leucine and sodium chloride, and stirred until all the components have completely dissolved.
  • Sodium hyaluronate is added separately to 100 kg of purified water, and stirred until the component has completely dissolved.
  • The two solutions are combined and made up to the final volume of 144 litres with purified water, checking that the pH value is between 6 and 7, and adjusting with citric acid or sodium bicarbonate if necessary.
  • Finally, the solution is filtered through an 0.22 μm filter under sterile conditions and placed in a container.
  • Pharmacological Trial
  • The protective and regenerative efficacy of the artificial tears according to the invention in reconstituting the corneal epithelium and stromal tissue in the case of pathological, traumatic, surgical, or parasurgical corneal lesions was investigated.
  • 300 eyes of 200 patients were examined:
      • 100 eyes of 50 patients suffering from slight, moderate or serious alterations of the tear film (Group A);
      • 80 eyes of 40 patients who underwent laser surgery (PRK) (Group B);
      • 20 eyes of 20 patients suffering from relapsing and/or persistent corneal ulcers (Group C);
      • 84 eyes of 84 patients who underwent cataract removal surgery, namely phacoemulsification with IOL implantation (Group D).
  • Cytomorphological study of the eye surface with confocal scanning electron microscopy (SEM) made it possible to analyse the histological modifications of the epithelial cells, and especially the microvilli. The Schimer test and BUT were used for the staging of the tear deficiency.
  • Regeneration of the epithelial microvilli, the fundamental substrate for effective restoration of the glycocalyx, and consequently the tear film, was observed in Group A. The patients already perceived a noticeable benefit after 10 days of treatment, with a drastic reduction in the typical symptoms of dry eye.
  • In Group B, the post-operative re-epithelialisation time was shortened from the usual 4-6 days to 2-3 days, and the administration of artificial tears, even after re-epithelialisation was complete, proved to prevent the appearance of haze and the dry eye syndrome typical of the first few months after surgery.
  • In Group C, re-epithelialisation and stability of the epithelium were obtained, without relapses, and where the ulcer had been already present for several weeks, complete re-epithelialisation was achieved.
  • Early healing of the corneal tunnel, with a definite reduction in the typical discomfort felt by the patient, was observed in Group D only a few days after the cataract operation.

Claims (19)

1-5. (canceled)
6. An ophthalmic pharmaceutical composition comprising as active ingredient a combination of:
a) glycine and proline; and
b) sodium hyaluronate.
7. The ophthalmic pharmaceutical composition of claim 6, the composition further comprising as active ingredient:
c) lysine and leucine.
8. The ophthalmic pharmaceutical composition of claim 6, wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate are comprised within the following percentage ranges by weight:
glycine 0.01 to 0.5%;
L-proline: 0.09 to 0.06%, and
sodium hyaluronate; 0.5 to 0.1%.
9. The ophthalmic pharmaceutical composition of claim 7, wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine are comprised within the following percentage ranges by weight:
L-lysine hydrochloride: 0.01 to 0.02%; and
L-leucine: 0.02 to 0.005%.
10. The ophthalmic pharmaceutical composition of claim 6, wherein proline is L-proline, and wherein glycine, L-proline and sodium hyaluronate have the following percentage ranges by weight:
glycine: 0.1%
L-proline: 0.075%; and
sodium hyaluronate: 0.3%.
11. The ophthalmic pharmaceutical composition of claim 7, wherein lysine is L-lysine, leucine is L-leucine and wherein L-lysine and L-leucine have the following percentage ranges by weight:
L-lysine hydrochloride: 0.014%, and
L-leucine: 0.011%
12. The ophthalmic pharmaceutical composition of claim 6, wherein the composition is in form of eyedrops, artificial tears, ointment or gel.
13. The ophthalmic pharmaceutical composition of claim 7, wherein the composition is in form of eyedrops, artificial tears, ointment or gel.
14. The ophthalmic pharmaceutical composition of claim 8, wherein the composition is in form of eyedrops, artificial tears, ointment or gel.
15. The ophthalmic pharmaceutical composition of claim 9, wherein the composition is in form of eyedrops, artificial tears, ointment or gel
16. The ophthalmic pharmaceutical composition of claim 10 wherein the composition is in form of eyedrops, artificial tears, ointment or gel.
17. The ophthalmic pharmaceutical composition of claim 11 wherein the composition is in form of eyedrops, artificial tears, ointment or gel.
18. A method to treat a corneal ulceration in a patient, the method comprising
administering to the patient the ophthalmic pharmaceutical composition of claim 6.
19. A method to treat a corneal ulceration in a patient, the method comprising
administering to the patient the ophthalmic pharmaceutical composition of claim 7.
20. A method to treat a lesion of pathological, traumatic, surgical, or parasurgical origin in a patient, the method comprising
administering to the patient the ophthalmic pharmaceutical composition of claim 6.
21. A method to treat a lesion of pathological, traumatic, surgical, or parasurgical origin in a patient, the method comprising
administering to the patient the ophthalmic pharmaceutical composition of claim 7.
22. A method to treat symptoms of dry eye in a patient, the method comprising
administering to the patient the ophthalmic pharmaceutical composition of claim 6.
23. A method to treat symptoms of dry eye in a patient, the method comprising
administering to the patient the ophthalmic pharmaceutical composition of claim 7.
US12/091,481 2005-10-26 2006-10-16 Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate Abandoned US20080249065A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2005A002036 2005-10-26
IT002036A ITMI20052036A1 (en) 2005-10-26 2005-10-26 PHARMACEUTICAL COMPOSITIONS OPHTHALMIC BASED ON AMINO ACIDS AND SODIUM HYALURONATE
PCT/EP2006/009967 WO2007048523A1 (en) 2005-10-26 2006-10-16 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009967 A-371-Of-International WO2007048523A1 (en) 2005-10-26 2006-10-16 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/964,522 Continuation US8524687B2 (en) 2005-10-26 2010-12-09 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Publications (1)

Publication Number Publication Date
US20080249065A1 true US20080249065A1 (en) 2008-10-09

Family

ID=37561156

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/091,481 Abandoned US20080249065A1 (en) 2005-10-26 2006-10-16 Ophthalmic Pharmaceutical Compositions Based on Amino Acids and Sodium Hyaluronate
US12/964,522 Active 2026-11-02 US8524687B2 (en) 2005-10-26 2010-12-09 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/964,522 Active 2026-11-02 US8524687B2 (en) 2005-10-26 2010-12-09 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate

Country Status (11)

Country Link
US (2) US20080249065A1 (en)
EP (1) EP1940381B1 (en)
JP (1) JP5312946B2 (en)
KR (1) KR20080074107A (en)
AT (1) ATE451916T1 (en)
CA (1) CA2627215C (en)
DE (1) DE602006011196D1 (en)
ES (1) ES2335437T3 (en)
IT (1) ITMI20052036A1 (en)
PL (1) PL1940381T3 (en)
WO (1) WO2007048523A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261915A1 (en) * 2005-10-26 2008-10-23 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) * 2005-10-26 2008-11-20 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate
US20110287064A1 (en) * 2010-05-19 2011-11-24 Heraeus Medical Gmbh Antibiotic coating
US20120316217A1 (en) * 2009-12-21 2012-12-13 Professional Dietetics S.R.L. combination for the treatment of osteoarthritis
EP2504001B1 (en) 2009-11-26 2015-03-04 Professional Dietetics S.r.l. Combination for the treatment of radiation- or chemotherapy-induced mucositis

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010277668A1 (en) * 2009-07-27 2012-03-01 Ciro Caruso Ophthalmic solution for protecting internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique
US20120264681A1 (en) * 2010-11-08 2012-10-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
AT511164A1 (en) 2011-03-03 2012-09-15 Croma Pharma Gmbh USE OF A VISCOELASTIC FLUID FOR THE MANUFACTURE OF A MEDICINE PRODUCT FOR SURGICAL TREATMENT OF THE EYE
ITMI20110954A1 (en) * 2011-05-26 2012-11-27 Professional Dietetics Srl COMBINATIONS FOR THE TREATMENT OF VAGINAL OR RECTAL MUCOSITES
ES2604816B1 (en) * 2015-09-09 2018-01-29 Farmalider, S.A. Pharmaceutical composition of tramadol for ophthalmic use
IT201600116727A1 (en) * 2016-11-18 2018-05-18 Univ Politecnica Delle Marche COMPOSED FOR THE HEALING OF WOUNDS
AU2019311846B2 (en) 2018-07-27 2023-02-23 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
EP4110393A1 (en) 2020-02-28 2023-01-04 Immunologik GmbH Inhibitors of human deubiquitinases for the treatment of coronaviral infections
US20230165851A1 (en) 2020-04-27 2023-06-01 Immunologik Gmbh 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
BR112022025134A2 (en) 2020-06-10 2022-12-27 Metriopharm Ag 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE, COMPOSITION, COMBINATION AND METHOD OF TREATMENT OF A CORONAVIRAL INFECTION
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
WO2022042873A1 (en) 2020-08-27 2022-03-03 Immunologik Gmbh Pharmaceutically acceptable lectins derived from plants, fungi and bacteria for the treatment of sars-cov-2 infections
IT202100029726A1 (en) 2021-11-24 2023-05-24 Professional Dietetics Spa OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF CORNEAL LESIONS
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707354A (en) * 1985-06-17 1987-11-17 Alpen Tau, Inc. Mature skin treatment and protectant compositions and methods of using same
US5741817A (en) * 1994-07-22 1998-04-21 Chowhan; Masood Use of low molecular weight amino acids in ophthalmic compositions
US20020013359A1 (en) * 2000-06-07 2002-01-31 Dioguardi Francesco Saverio Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds
US20030021834A1 (en) * 1996-08-07 2003-01-30 Petito George D. Method for use of hyaluronic acid in wound management
US20030091652A1 (en) * 2001-11-13 2003-05-15 Suhail Ishaq Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US20040004744A1 (en) * 2002-07-02 2004-01-08 Peter Haider Apparatus and method for obtaining image information from an image original
US20040006348A1 (en) * 1999-08-26 2004-01-08 The Spineology Group, Llc Tools and method for processing and injecting bone graft material
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20080261915A1 (en) * 2005-10-26 2008-10-23 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) * 2005-10-26 2008-11-20 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6084225A (en) * 1983-10-17 1985-05-13 Hiroko Shimizu Eye drop
JPH0723317B2 (en) * 1988-03-17 1995-03-15 生化学工業株式会社 Corneal epithelial disorder treatment
JP3050898B2 (en) * 1990-07-06 2000-06-12 千寿製薬株式会社 Aqueous pharmaceutical preparation
JPH10290830A (en) * 1997-04-18 1998-11-04 Ofutekusu:Kk Adjuvant for operating on eye
US6645948B2 (en) 1998-03-24 2003-11-11 George D. Petito Nutritional composition for the treatment of connective tissue
US6654948B1 (en) * 1999-10-12 2003-11-25 International Business Machines Corporation Methods and apparatus for partial and consistent monitoring of object-oriented programs and systems
ITTO20010804A1 (en) * 2001-08-08 2003-02-08 Professional Dietetics Srl COMPOSITIONS BASED ON AMINO ACIDS, SUITABLE FOR THERAPY FOR CICATRIZATION AND / OR REPAIR OF INJURIES AND INJURIES, IN PARTICULAR FOR THE APP
EP1539193A4 (en) * 2002-07-03 2010-05-05 Pericor Science Inc Compositions of hyaluronic acid and methods of use
FR2849383B1 (en) * 2002-12-26 2005-09-30 Jean Noel Thorel TROPHIC COMPOSITION IN AQUEOUS MEDIUM, AND ITS APPLICATIONS, IN PARTICULAR IN OPHTHALMOLOGY
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707354A (en) * 1985-06-17 1987-11-17 Alpen Tau, Inc. Mature skin treatment and protectant compositions and methods of using same
US5741817A (en) * 1994-07-22 1998-04-21 Chowhan; Masood Use of low molecular weight amino acids in ophthalmic compositions
US20030021834A1 (en) * 1996-08-07 2003-01-30 Petito George D. Method for use of hyaluronic acid in wound management
US20040006348A1 (en) * 1999-08-26 2004-01-08 The Spineology Group, Llc Tools and method for processing and injecting bone graft material
US20020013359A1 (en) * 2000-06-07 2002-01-31 Dioguardi Francesco Saverio Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US20030091652A1 (en) * 2001-11-13 2003-05-15 Suhail Ishaq Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US20040004744A1 (en) * 2002-07-02 2004-01-08 Peter Haider Apparatus and method for obtaining image information from an image original
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20080261915A1 (en) * 2005-10-26 2008-10-23 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) * 2005-10-26 2008-11-20 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261915A1 (en) * 2005-10-26 2008-10-23 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate
US20080287392A1 (en) * 2005-10-26 2008-11-20 Solartium Llc Wound-Healing Pharmaceutical Compositions in the Form of a Cream Based on Amino Acids and Sodium Hyaluronate
EP2504001B1 (en) 2009-11-26 2015-03-04 Professional Dietetics S.r.l. Combination for the treatment of radiation- or chemotherapy-induced mucositis
US20120316217A1 (en) * 2009-12-21 2012-12-13 Professional Dietetics S.R.L. combination for the treatment of osteoarthritis
US20110287064A1 (en) * 2010-05-19 2011-11-24 Heraeus Medical Gmbh Antibiotic coating

Also Published As

Publication number Publication date
ES2335437T3 (en) 2010-03-26
PL1940381T3 (en) 2010-05-31
ATE451916T1 (en) 2010-01-15
EP1940381B1 (en) 2009-12-16
US20110077219A1 (en) 2011-03-31
KR20080074107A (en) 2008-08-12
DE602006011196D1 (en) 2010-01-28
ITMI20052036A1 (en) 2007-04-27
JP2009513586A (en) 2009-04-02
WO2007048523A1 (en) 2007-05-03
EP1940381A1 (en) 2008-07-09
CA2627215C (en) 2015-03-24
JP5312946B2 (en) 2013-10-09
CA2627215A1 (en) 2007-05-03
US8524687B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
US8524687B2 (en) Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate
US7871646B2 (en) Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin
US5811446A (en) Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6984628B2 (en) Ophthalmic compositions comprising trefoil factor family peptides
MX2012005816A (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions.
US20220332773A1 (en) Silk-derived protein for treating inflammation
KR20050086937A (en) Use of rimexolone in the treatment of dry eye
US20110275688A1 (en) Ketorolac compositions for corneal wound healing
De Monchy et al. Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): a case report
US20210315805A1 (en) Ketorolac compositions for corneal wound healing
US8426384B2 (en) Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
Aldavood et al. Effect of acetylcysteine on experimental corneal wounds in dogs
TW443931B (en) A therapeutic agent for the treatment of disorders of corneal and conjuntival epithelia
WO1999038497A2 (en) Ophthalmic composition
WO2017030328A1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
WO1998013038A1 (en) Subepithelial turbidity inhibitor
Higaki et al. Corneal collagen shields for ocular drug delivery
Mallias et al. Fungal keratitis after Descemet stripping automated endothelial keratoplasty
KR20150067517A (en) Pharmaceutical composition for preventing or treating of scarring after glaucoma filteration surgery
Gholipour et al. Effect of dexamethasone in combination with acetylcysteine at different times on corneal wound healing in dogs

Legal Events

Date Code Title Description
AS Assignment

Owner name: SOLARTIUM LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONTI, FRANCO;REEL/FRAME:020853/0679

Effective date: 20080317

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PROFESSIONAL DIETETICS S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLARTIUM ENTERPRISED LIMITED;REEL/FRAME:026223/0844

Effective date: 20110117